Google
Trusted Resources: News & Events
Latest announcements and gatherings
Bluebird Bio Presents Data From LentiGlobin Gene Therapy Trial
Bluebird Bio’s investigational gene therapy LentiGlobin safely prevents serious vaso-occlusive crises and acute chest syndrome in adolescents and adults with severe sickle cell disease (SCD), according to recent data from a Phase 1/2 clinical trial.
The findings, “Outcomes in patients treated with LentiGlobin for sickle cell disease (SCD) gene therapy: updated results from the Phase 1/2 HGB-206 group C study,” were recently presented at the virtual 25th European Hematology Association (EHA) Annual Congress.
“The promising results of this study, which show patients have an almost complete elimination of VOCs [vaso-occlusive crises] and ACS [acute chest syndrome], suggest LentiGlobin … has real potential to provide a significant impact for people living with sickle cell disease,” Julie Kanter, MD, said in a press release.
+myBinderRelated Content
-
Sickle Cell Patient Receives CRISPR Gene TherapyMany human diseases can be traced back t...
-
Researchers raise funds for phase 1 trial to test medical cannabis in sickle cell diseaseThe Sickle Cell Foundation of Georgia ...
-
Statement on NHLBI Decision to Pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Si...bluebird bio, Inc. suspended its clinica...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
-
Podcast: How New Gene Therapies for SCD May Impact Women’s FertilityAs we closed 2023, the Food and Drug Ad...
-
SPCI Launched the SCOT (Sickle Cell Omega-3 Treatment) Trial in the United States with an Investigator Meeting Held ...Sancilio Pharmaceuticals Company, Inc. (...
-
The first two years of life in sickle cell anemia infants: A results of a comprehensive longitudinal studyInfancy is a critical time during which ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.